Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.

Efuni, Elizaveta; Cytryn, Samuel; Boland, Patrick; Niewold, Timothy B; Pavlick, Anna; Weber, Jeffrey; Sandigursky, Sabina

Efuni, Elizaveta; Cytryn, Samuel; Boland, Patrick; Niewold, Timothy B; Pavlick, Anna; Weber, Jeffrey; Sandigursky, Sabina.

Affiliation

Efuni E; From the Department of Medicine.
Cytryn S; From the Department of Medicine.
Boland P; From the Department of Medicine.
Niewold TB; Divisions of Rheumatology.
Pavlick A; Oncology, Department of Medicine, New York University School of Medicine/NYU Langone Health, New York, NY.
Weber J; Oncology, Department of Medicine, New York University School of Medicine/NYU Langone Health, New York, NY.
Sandigursky S; Divisions of Rheumatology.

J Clin Rheumatol ; 27(7): 267-271, 2021 Oct 01.

Article in En | MEDLINE | ID: mdl-31977647

Subject(s)

Arthritis, Rheumatoid; Autoimmune Diseases; Neoplasms; Arthritis, Rheumatoid/drug therapy; Autoimmune Diseases/drug therapy; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Neoplasms/drug therapy; Neoplasms/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Autoimmune Diseases / Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Rheumatol Journal subject: FISIOLOGIA / ORTOPEDIA / REUMATOLOGIA Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google